HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pascal V Grundler Selected Research

Terbium-161

1/2022Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pascal V Grundler Research Topics

Disease

3Neoplasms (Cancer)
01/2022 - 05/2020

Drug/Important Bio-Agent (IBA)

2Edotreotide (SMT 487)IBA
01/2022 - 04/2021
2TerbiumIBA
01/2022 - 04/2021
2Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2022 - 04/2021
2Radioisotopes (Radionuclides)IBA
04/2021 - 05/2020
1Somatostatin Receptors (Somatostatin Receptor)IBA
01/2022
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2022
1Peptides (Polypeptides)IBA
01/2022
1Terbium-161IBA
01/2022
1IsotopesIBA
04/2021
1LutetiumIBA
04/2021

Therapy/Procedure

1Therapeutics
05/2020